Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subconjunctival ranibizumab (Lucentis) for corneal neovascularization – phase I/II pilot study
2010-020683-38Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ranibizumab in corneal neovascularization (CNV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Primary safety/tolerability endpoint. Started Jun 2010; status: active.
02
Drugs
ranibizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on 2010-020683-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020683-38.